Erasca, Inc. (ERAS)
16.19
-0.07
(-0.43%)
USD |
NASDAQ |
Sep 04, 16:00
16.19
0.00 (0.00%)
After-Hours: 20:00
Erasca Research and Development Expense (Quarterly) : 35.90M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 35.90M |
| March 31, 2026 | 27.26M |
| December 31, 2025 | 23.24M |
| September 30, 2025 | 22.47M |
| June 30, 2025 | 21.17M |
| March 31, 2025 | 25.97M |
| December 31, 2024 | 26.12M |
| September 30, 2024 | 27.63M |
| June 30, 2024 | 33.03M |
| March 31, 2024 | 28.57M |
| December 31, 2023 | 24.80M |
| September 30, 2023 | 25.21M |
| June 30, 2023 | 26.22M |
| Date | Value |
|---|---|
| March 31, 2023 | 27.58M |
| December 31, 2022 | 129.36M |
| September 30, 2022 | 28.18M |
| June 30, 2022 | 27.49M |
| March 31, 2022 | 29.43M |
| December 31, 2021 | 24.13M |
| September 30, 2021 | 21.63M |
| June 30, 2021 | 23.09M |
| March 31, 2021 | 15.92M |
| December 31, 2020 | 64.06M |
| September 30, 2020 | 9.143M |
| June 30, 2020 | 5.863M |
| March 31, 2020 | 22.22M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Revolution Medicines, Inc. | 392.47M |
| Tango Therapeutics, Inc. | 36.77M |
| Arrowhead Pharmaceuticals, Inc. | 192.06M |
| Oncolytics Biotech, Inc. | 4.262M |
| Sangamo Therapeutics, Inc. | 26.57M |